September 9, 2024Journal of Clinical Oncology
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates improved progression-free survival with datopotamab deruxtecan in advanced non-small cell lung cancer, highlighting benefits in nonsquamous histology.
Key Points
- Progression-free survival improved significantly with datopotamab deruxtecan over docetaxel, with benefits concentrated in nonsquamous non-small cell lung cancer.
- Median progression-free survival reached 4.4 months with datopotamab deruxtecan versus 3.7 months for docetaxel, demonstrating a statistically significant delay in disease progression.
- Randomized phase III trial evaluation revealed fewer severe adverse events with datopotamab deruxtecan, supporting its use while monitoring for interstitial lung disease.
Cite This Study
Ahn et al. (2024) studied this question.